QuidelOrtho Corp (QDEL) Financial Statements
Industry: In Vitro & In Vivo Diagnostic Substances
In fiscal 2025, QuidelOrtho reported revenue of $2.73B, down 1.9% from $2.78B the year before. Net income was -$1.13B (a -41.5% net margin), or -$16.69 per diluted share. Operating margin was -33.7%. Operating activities generated $105.2M of cash, leaving -$83.0M of free cash flow. At fiscal year end, QuidelOrtho held $5.77B in total assets against $3.85B in total liabilities, including $169.8M of cash and equivalents.
Open the full interactive QuidelOrtho financials → Quarterly statements, key ratios, valuation history and price charts.
QuidelOrtho Key Stats
| Share Price | $14.10 |
|---|---|
| Market Cap | $963.0M |
| Revenue YoY Growth | -1.9% |
| 52-Week Range | $9.96 – $35.38 |
| Shares Outstanding | 68.3 million (basic, 2026 Q2) |
QuidelOrtho Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $3.27B | $3.00B | $2.78B | $2.73B |
| Operating Income | $843.7M | $139.1M | -$1.96B | -$919.2M |
| Pre-Tax Income | $735.9M | -$29.1M | -$2.13B | -$1.11B |
| Income Tax | $187.2M | -$19.0M | -$79.5M | $24.1M |
| Net Income | $548.7M | -$10.1M | -$2.05B | -$1.13B |
| Diluted EPS | $9.56 | -$0.15 | -$30.54 | -$16.69 |
QuidelOrtho Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $699.9M | $723.6M | $619.8M | $630.9M |
| Net Income | -$733.0M | -$130.7M | -$91.8M | -$92.9M |
| Diluted EPS | -$10.78 | -$1.93 | -$1.35 | -$1.36 |
QuidelOrtho Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash & Equivalents | $292.9M | $118.9M | $98.3M | $169.8M |
| Current Assets | $1.58B | $1.31B | $1.22B | $1.45B |
| Total Assets | $8.86B | $8.56B | $6.42B | $5.77B |
| Current Liabilities | $1.01B | $833.8M | $998.8M | $966.1M |
| Total Long-Term Debt | $2.85B | $2.41B | $2.48B | $2.65B |
| Total Liabilities | $3.92B | $3.56B | $3.44B | $3.85B |
| Shareholders' Equity | $4.93B | $5.01B | $2.98B | $1.92B |
QuidelOrtho Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | $885.3M | $280.2M | $83.0M | $105.2M |
| Cash From Investing | -$1.64B | -$187.6M | -$149.9M | -$192.7M |
| Cash From Financing | $252.0M | -$265.8M | $48.8M | $155.8M |
| Free Cash Flow | $744.4M | $70.9M | -$112.1M | -$83.0M |
Figures from QuidelOrtho's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full QuidelOrtho financials page for every line item.
QuidelOrtho Company Profile
| Ticker | QDEL |
|---|---|
| Exchange | Nasdaq |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Headquarters | San Diego, California |
| Fiscal Year End | January 1 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001906324 |
Frequently Asked Questions
What was QuidelOrtho's revenue in fiscal 2025?
QuidelOrtho (QDEL) reported revenue of $2.73B for fiscal 2025.
What is QuidelOrtho's annual revenue history?
QuidelOrtho's annual revenue by fiscal year: 2022: $3.27B; 2023: $3.00B; 2024: $2.78B; 2025: $2.73B.
What was QuidelOrtho's net income in fiscal 2025?
QuidelOrtho reported net income of -$1.13B for fiscal 2025.
What was QuidelOrtho's earnings per share (EPS) in fiscal 2025?
QuidelOrtho's diluted EPS was -$16.69 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did QuidelOrtho generate in fiscal 2025?
QuidelOrtho generated -$83.0M of free cash flow in fiscal 2025.
What was QuidelOrtho's revenue last quarter?
In its most recent reported quarter (2026 Q2), QuidelOrtho reported revenue of $630.9M.
How much debt does QuidelOrtho have?
QuidelOrtho reported $2.65B of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of QuidelOrtho are outstanding?
QuidelOrtho reported a weighted average of 68.3 million basic shares outstanding in 2026 Q2.
What is QuidelOrtho's market cap?
Based on its latest closing price, QuidelOrtho (QDEL) has a market capitalization of about $963.0M.
When does QuidelOrtho's fiscal year end?
QuidelOrtho's fiscal year end, as registered with the SEC, is January 1.
Where is QuidelOrtho headquartered?
QuidelOrtho lists its business address in San Diego, California in its SEC filings.
QuidelOrtho Competitors & Similar Companies
See all 15 In Vitro & In Vivo Diagnostic Substances companies →